Summit Therapeutics
SMMT
45 hedge funds and large institutions have $3.8M invested in Summit Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 11 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
0% more funds holding
Funds holding: 45 → 45 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
7.05% less ownership
Funds ownership: 8.64% → 1.59% (-7.1%)
55% less capital invested
Capital invested by funds: $8.47M → $3.8M (-$4.68M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$305K |
| 2 |
Morgan Stanley
New York
|
+$161K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$159K |
| 4 |
BlackRock
New York
|
+$134K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$65.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$5.6M |
| 2 |
AGM
Alpine Global Management
New York
|
-$300K |
| 3 |
E
Ergoteles
New York
|
-$101K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$82K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$64.2K |
SMMT Hedge Fund Activity: Q3 2022 in Review
45 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2022, worth a combined $3.8M — down 55% from $8.47M a quarter earlier.
Fund positioning in SMMT was balanced in Q3 2022: 11 funds opened new positions, 11 closed out, 15 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $305K. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $5.6M sold.
- 45 institutional investors held Summit Therapeutics (SMMT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $3.8M of Summit Therapeutics stock for Q3 2022, down 55% quarter-over-quarter.
- 11 funds opened new Summit Therapeutics positions in Q3 2022 and 11 closed out, a net change of 0 holders.
- The largest Summit Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $305K added.
- The largest Summit Therapeutics seller in Q3 2022 was Polar Capital Holdings, an estimated $5.6M sold.
Based on aggregated 13F filings for Q3 2022.